Clinical trial NCT01662687: Phase 4 Trial to Evaluate the Efficacy and Safety of Sancuso Patch in CINV (Chemotherapy-induced Nausea and Vomiting) Associated With the Administration of MEC (Moderately Emetogenic Chemotherapy)
Official title: Randomized Study of the Efficacy and Safety of Transdermal Granisetron Compared With Intravenous and Oral Agent in the Control of Nausea and Vomiting Induced by Moderately Emetogenic Chemotherapy
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Chemotherapy-induced Acute or Delayed Nausea and Vomiting (CINV)
Lead sponsor: LG Life Sciences
Sponsor class: INDUSTRY
First posted: 2012-08-10
Enrollment: 276
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Multicenter, randomized, open-label, paralled-group, active-controlled study. The study is to demonstrate non-inferiority of the Granisetron Transdermal Delivery System (GTDS) compared with the intravenous and oral Granisetron in the prevention of CINV associated with moderately emetogenic Chemotherapy.

Patients scheduled to receive the one cycle of a ME chemotherapy regimen administered for 1-4 days will attend a Screening Visit 2 to 28 days before start of ME chemotherapy. Eligible patients will be randomized to 1 of 2 treatment groups at the Randomization Visit (1 to 2 days prior to ME chemotherapy).

* Sancuso patch
* Kytril inj.+Kytril tab.

The patch will be applied 2days (48-24h) prior to first daily dose of the moderately emetogenic chemotherapy regimen and remain in place for 6 days. The patient will be assessed daily until 4days after first chemotherapy administration. Adverse Events (AEs) will be collected until 14 days after the final dose of IP. Non-serious AEs will be followed-up until 14 days after the final dose of IP. Serious adverse events will be followed-up until they are resolved, stable or until the patient is lost to follow-up.


Eligibility criteria: Inclusion Criteria:

1. Male or female aged over 20 yrs
2. Histologically and/or cytologically proven cancer patients
3. Eastern Cooperative Oncology Group performance status 0, 1, 2
4. A cycle of moderately emetogenic chemotherapy(NCCN Guidelines)
5. Life expectancy of ≥ 3 months
6. Normal liver function and renal function(total bilirubin ≤ 1.5 ULN, AST/ALT ≤ 2.5 ULN, in case of liver metastases AST/ALT ≤ 5 ULN, serum creatinine ≤ 1.5 ULN) patients
7. Patients who signed the informed consent form

Exclusion Criteria:

A. Previous History

1. Hypersensitivity to adhesive plasters
2. Contraindications to 5-HT3 receptor antagonists
3. Any other relevant medical history (at the discretion of the investigator)

B. Concomitant Medical Condition

1. Current alcohol, drug or medication abuse
2. Currently pregnant or breast feeding women, including planning pregnancy
3. Clinically relevant abnormal laboratory values (at the discretion of the investigator)
4. Clinically relevant heart, hepatic, renal, infectious, neurological or psychiatric disorders, or any other major systemic illness (at the discretion of the investigator)
5. Any cause for nausea and vomiting other than CINV
6. Any episode of retching, vomiting or uncontrolled nausea in the 72 h period prior to the chemotherapy administration
7. Clinically relevant abnormal ECG parameters (at the discretion of the investigator)

C. Concomitant Therapy/Medication

1. Concomitant radiotherapy of total body, brain or upper abdomen within one week prior to the study entry or planned during the study
2. Intake of medication to control the symptoms of a brain tumor, brain metastasis or seizure disorder or neuropathy (unless peripheral neuropathy at the discretion of the investigator)
3. Patients using selective serotonin reuptake inhibitor (SSRI) antidepressants (unless a stable dose for the duration of the study)
4. Receipt of a narcotic analgesics (acceptable at the discretion of the investigator)
5. Receipt of any other clinical trial drug \< 30 days before the study or during the study
6. Scheduled to receive a neurokinin NK1 receptor antagonist, dopamine receptor antagonist or another 5-HT3 receptor antagonist at 72 h prior to the administration of the chemotherapy or scheduled to do those medication during chemotherapy duration
7. Drugs known to increase the QTc interval (unless a stable dose for the duration of the study at the discretion of the investigator)

D. Other

1. Patients unlikely to comply with the study protocol (at the discretion of the investigator), e.g. uncooperative attitude, inability to return for follow-up visits and unlikelihood of completing the study
2. The patch adhesion level was not more than 50% on the day of chemotherapy or the patch was not attached within two days before the chemotherapy

Primary outcomes:
measure: The percentage of patients achieving Complete Response (CR) without rescue therapy from the first administration until 24h after the start of the last day's administration of the ME chemotherapy regimen
timeFrame: from the first administration until 24h after the start of the last day's administration of the ME chemotherapy regimen
Secondary outcomes:
measure: The percentage of patients achieving Complete Response (CR)
timeFrame: overall (Day 1~4)
measure: The percentage of patients achieving Complete Control (CC) without rescue therapy from the first administration until 24h after the start of the last day's administration of the ME chemotherapy regimen
timeFrame: from the first administration until 24h after the start of the last day's administration of the ME chemotherapy regimen
measure: The percentage of patients achieving Complete Control (CC)
timeFrame: overall (Day 1~4)
measure: severity of nausea
timeFrame: overall (Day 1~4)
measure: severity of vomiting
timeFrame: overall (Day 1~4)
measure: Frequency of nausea from the first administration until 24h after the start of the last day's administration of the ME chemotherapy regimen
timeFrame: from the first administration until 24h after the start of the last day's administration of the ME chemotherapy regimen
measure: Frequency of vomiting from the first administration until 24h after the start of the last day's administration of the ME chemotherapy regimen
timeFrame: from the first administration until 24h after the start of the last day's administration of the ME chemotherapy regimen
measure: Patient's satisfaction with anti-emetic therapy (Changes from Baseline to Day 5)
timeFrame: from baseline to Day 5
measure: The percentage of patients achieving Complete Response (CR)
timeFrame: per day (Day 1, 2, 3, 4)
measure: The percentage of patients achieving Complete Control (CC)
timeFrame: per day (Day 1, 2, 3, 4)
measure: severity of nausea
timeFrame: per day (Day 1, 2, 3, 4)
measure: severity of vomiting
timeFrame: per day (Day 1, 2, 3, 4)
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Samsung Medical Center
Study officials:
affiliation: Samsung Medical Center
name: Jin Seok Ahn, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Asan Medical Center
name: Tae Won Kim, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Gachon University Gil Medical Center
name: Dong Bok Shin, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Kim JE, Hong YS, Lee JL, Kim KP, Park SJ, Sym SJ, Shin DB, Lee J, Park YS, Ahn JS, Kim TW. A randomized study of the efficacy and safety of transdermal granisetron in the control of nausea and vomiting induced by moderately emetogenic chemotherapy in Korean patients. Support Care Cancer. 2015 Jun;23(6):1769-77. doi: 10.1007/s00520-014-2507-6. Epub 2014 Dec 3.